Facile discovery of surrogate cytokine agonists.
(2022) Cell 185: 1414
Authors: Yen, M., Ren, J., Liu, Q., Glassman, C.R., Sheahan, T.P., Picton, L.K., Moreira, F.R., Rustagi, A., Jude, K.M., Zhao, X., Blish, C.A., Baric, R.S., Su, L.L., Garcia, K.C.
Abstract
Cytokines are powerful immune modulators that initiate signaling through receptor dimerization, but natural cytokines have structural limitations as therapeutics. We present a strategy to discover cytokine surrogate agonists by using modular ligands that exploit induced proximity and receptor dimer geometry as pharmacological metrics amenable to high-throughput screening. Using VHH and scFv to human interleukin-2/15, type-I interferon, and interleukin-10 receptors, we generated combinatorial matrices of single-chain bispecific ligands that exhibited diverse spectrums of functional activities, including potent inhibition of SARS-CoV-2 by surrogate interferons. Crystal structures of IL-2R:VHH complexes revealed that variation in receptor dimer geometries resulted in functionally diverse signaling outputs. This modular platform enabled engineering of surrogate ligands that compelled assembly of an IL-2R/IL-10R heterodimer, which does not naturally exist, that signaled through pSTAT5 on T and natural killer (NK) cells. This cytokine med-chem approach, rooted in principles of induced proximity, is generalizable for discovery of diversified agonists for many ligand-receptor systems.
Facile discovery of surrogate cytokine agonists.
(2022) Cell 185: 1414
Authors: Yen, M., Ren, J., Liu, Q., Glassman, C.R., Sheahan, T.P., Picton, L.K., Moreira, F.R., Rustagi, A., Jude, K.M., Zhao, X., Blish, C.A., Baric, R.S., Su, L.L., Garcia, K.C.
Abstract
Cytokines are powerful immune modulators that initiate signaling through receptor dimerization, but natural cytokines have structural limitations as therapeutics. We present a strategy to discover cytokine surrogate agonists by using modular ligands that exploit induced proximity and receptor dimer geometry as pharmacological metrics amenable to high-throughput screening. Using VHH and scFv to human interleukin-2/15, type-I interferon, and interleukin-10 receptors, we generated combinatorial matrices of single-chain bispecific ligands that exhibited diverse spectrums of functional activities, including potent inhibition of SARS-CoV-2 by surrogate interferons. Crystal structures of IL-2R:VHH complexes revealed that variation in receptor dimer geometries resulted in functionally diverse signaling outputs. This modular platform enabled engineering of surrogate ligands that compelled assembly of an IL-2R/IL-10R heterodimer, which does not naturally exist, that signaled through pSTAT5 on T and natural killer (NK) cells. This cytokine med-chem approach, rooted in principles of induced proximity, is generalizable for discovery of diversified agonists for many ligand-receptor systems.